Table I.

Features of the Study Sample Stratified by the Ventilation Defect /Total Lung Volume Tercile Distribution

Variable	Sample	Lower Tercile (0.13 – 0.81%)	Middle Tercile (1.0–2.1%)	Upper Tercile (2.5–11.6%)	p
n	31	10	11	10
Enrollment Age (yr)	10 (3–17)	9 (4–16)	11 (3–17)	9 (3–17)	0.97**
Male sex n (%)	21 (68%)	7 (70%)	7 (64%)	7 (70%)	0.94
African American n (%)	10 (32%)	2 (20%)	4 (36%)	4 (40%)	0.48
Body Mass Index (kg/m2)	18.3 (14.7–33.6)	18.5 (17.1–29.0)	17.5 (14.7–33.6)	19.6 (14.7–31.5)	0.77
Birth Gestational Age (mo)	39 (24–39)	38 (28–39)	38 (27–39)	39 (24–39)	0.66
Age at First Wheeze (mo)	12 (2–108)	12 (2–60)	12 (2–24)	8 (2–108)	0.89
Hospital Admissions for Asthma (n)	1 (0–10)	1 (0–6)	1 (0–10)	6 (1–6)	0.16
Any ICU Admission for Asthma n (%)	8 (26%)	2 (20%)	2 (18%)	4 (40%)	0.46
Any Past Pneumonia n (%)	26 (84%)	8 (80%)	10 (91%)	8 (80%)	0.73
Family History Asthma n (%)	24 (77%)	9 (90%)	8 (73%)	7 (70%)	0.51
Daily ICS Dose (mcg fluticasone equiv.)	800 (0–2000)	445 (0–920)	460 (320 −2000)	860 (80–1600)	0.08
High Dose ICS n (%)	25 (81%)	6 (60%)	10 (91%)	9 (90%)	0.13
Daily Prednisone n (%)	7 (23%)	0 (0%)	2 (18%)	5 (50%)	0.03
Daily LABA n (%)	22 (71%)	5 (50%)	8 (73%)	9 (90%)	0.14
Montelukast n (%)	20 (64%)	5 (50%)	8 (73%)	7 (70%)	0.50
# Daily Controllers	3 (1–4)	2 (1–4)	3 (1–4)	4 (1–4)	0.05
cACT/ACT score	12 (8–25)	14 (11–25)	11 (8–23)	12 (9–14)	0.21
Asthma Event Score	0.83 (0.0–3.0)	0.83 (0.25–1.5)	0.66 (0.0–2.8)	0.87 (0.0–3.0)	0.84
Severe Asthma n (%)	20 (64%)	3 (30%)	7 (64%)	10 (100%)	0.005

^*Scaled variables shown as the median (min-max values);

^**Kruskal Wallis test corrected for multiple group comparisons.